Wells Fargo analyst Derek Archila raised the firm’s price target on aTyr Pharma (ATYR) to $25 from $17 and keeps an Overweight rating on the shares. The firm is increasing its probability of success to 50% that efzo demonstrates statistical significance steroid reduction but also benefits on QOL in the upcoming Phase 3 read out for pulmonary sarcoidosis in early September. Wells would be a buyer ahead of data.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATYR:
- Promising Phase 2 Results for aTyr Pharma’s Efzofitimod in SSc-ILD Boost Investor Confidence
- Positive Outlook on aTyr Pharma: Promising Phase 2 Results and Anticipation for Phase 3 Trials Justify Buy Rating
- aTyr Pharma announces interim analysis from Phase 2 EFZO-CONNECT
- aTyr Pharma management to meet with Piper Sandler
- Buy Rating for aTyr Pharma: Confidence in EFZO-FIT Phase 3 Trial Success